Inhibikase Therapeutics, Inc.
IKT- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001750149
No open-market purchases or sales by Inhibikase Therapeutics, Inc. insiders were filed in the last 90 days; 105 institutions reported holding it in 13F filings for Q2 2026, worth $239.2M in total; no superinvestor holds it.
Q3 2025 vs. Q2 2025
How the institutions holding Inhibikase Therapeutics, Inc. changed between Q2 2025 and Q3 2025.
All holders in Q3 2025All holders in Q2 2025
| Measure | Q2 2025 | Q3 2025 | Change |
|---|---|---|---|
| Holders | 48 | 54 | +6 |
| Shares | 54.5M | 55.0M | +452.4K (+0.8%) |
| Value | $106.3M | $89.0M | −$17.3M (−16.2%) |
New holders (8)
Institutions that held Inhibikase Therapeutics, Inc. at the end of Q3 2025 but not at the end of Q2 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Deutsche Bank AG | 80,496 | $130.4K | 0.00% |
| Citadel Advisors LLC | 71,670 | $116.1K | 0.00% |
| Virtu Financial LLC | 13,446 | $22.0K | 0.00% |
| Goldman Sachs Group Inc | 10,735 | $17.4K | 0.00% |
| Russell Investments Group, Ltd. | 7,702 | $12.5K | 0.00% |
| The PNC Financial Services Group, Inc. | 90 | $146 | 0.00% |
| SRS Capital Advisors, Inc. | 86 | $139 | 0.00% |
| CWM, LLC | 19 | $0 | 0.00% |
Sold out (2)
Institutions that held Inhibikase Therapeutics, Inc. at the end of Q2 2025 and filed for Q3 2025 without it.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| LMR Partners LLP | 31,092 | $60.6K |
| Raymond James Financial Inc | 1,000 | $1.95K |